AiCuris Completes Phase II Genital Herpes Trial with AIC316 Ahead of Time

10-Dec-2010 - Germany

AiCuris announced that the last subject has completed their Phase-II trial "A double-blind randomized placebo controlled dose-finding trial to investigate different doses of a new antiviral drug in subjects with genital HSV Type 2 infection".

The trial has been completed two months earlier than planned. Indeed, in the later stages of the trial, enrolment had to be restricted as the number of subjects was higher than the number that was required to be enrolled according to the trial protocol. “We were surprised by the interest in our trial and the number of requests for participation that we received from people infected with herpes simplex virus” said Dr. Burkhard Timmler, Associate Director Clinical Development at AiCuris. “In spite of available therapeutic options there seems to be a great demand for a new, well tolerated and efficacious drug for people suffering from genital herpes”.

AiCuris plans to have the first data available in early 2011. “We hope that the results will allow us to determine the efficacious dose of AIC316 and confirm the potential for once daily oral dosing in genital herpes. Our ultimate goal is to address the still existing unmet medical need in the field of genital herpes infections with this drug which acts by a unique mode of action”, adds Prof. Rübsamen-Schaeff, CEO of AiCuris.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Millennium and Abbott Initiate Phase I Trials of their First Genomically-Derived Drug Target for Obesity

Geoffrey McDonough appointed President and CEO of Swedish Orphan Biovitrum

ARIUS Research Signs Anti-Cancer Antibody Discovery Deal with Takeda - Three-Year Collaboration to look for Novel Cancer Treatments

Amorfix announces Michael Sonnenreich as new director and establishment of a scientific advisory board

ALTANA AG: Sale of pharmaceuticals business to Nycomed - Purchase price of approx. EUR4.5 billion

MediGene and The Johns Hopkins University Sign Development Collaboration for First Vaccine Candidates from MediGene's AAVLP Platform - Examination of product candidates for the prevention of HPV-associated diseases

Lexicon Genetics Initiates Clinical Trials of LX1031 for Irritable Bowel Syndrome

AMRI promotes Richard A. Saffee to Vice President and General Manager of Large Scale Manufacturing

Market Opportunities Abound for Life Science Suppliers in Multi-Billion Dollar U.S. Market for Biodefense Research

MIT biologists find that restoring the gene for cancer protein p53 slows spread of advanced tumors

Enzo Biochem Granted European Patent For Displacer Technology To Treat Gene Abnormalities - Methodology Could Make Possible Modification or Corrections of Cell Mutations

AbD Serotec Signs Agreement with Dana-Farber Cancer Institute for Anti-Infective Research